02:28 PM EDT, 04/11/2024 (MT Newswires) -- Ocuphire Pharma ( OCUP ) enrolled the first patient in the phase 3 trial of its Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery, the company said Thursday.

The trial is conducted under the US Food and Drug Administration's Special Protocol Assessment, the company said.

Shares of the company were down 1% in recent trading.

Price: 1.84, Change: -0.02, Percent Change: -1.08